Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850574 | 0.85 | ABHD6 (0.41) | P2RX3P2RX2ABHD6MGLLLOXL2 | |
| SCHEMBL23850304 | 0.83 | HSD11B1 (0.47) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL30490316 | 0.80 | ABHD6 (0.40) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL26631358 | 0.80 | GPR119 (0.46) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL29497063 | 0.79 | LOXL2 (0.46) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL25297104 | 0.79 | LOXL2 (0.46) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL20129206 | 0.78 | DGAT1 (0.55) | P2RX3P2RX2ABHD6GPR119 | |
| SCHEMBL25255551 | 0.77 | GPR119 (0.45) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL30395790 | 0.77 | GPR119 (0.45) | P2RX3P2RX2ABHD6GPR119MGLL | |
| SCHEMBL31171162 | 0.77 | GPR119 (0.43) | P2RX3P2RX2ABHD6GPR119MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | P2RX3 1119/4885P2RX2 951/4885PIK3CA 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.